In brief: BresaGen, Epitan

The company created by the merger between BresaGen's US-based stem cell therapy business and the San Diego based company Cythera has merged again with Novocell, a Californian company commercialising encapsulated cell technology for the treatment of diabetes and other diseases. The earlier merger left Bresagen (ASX:BGN) with about 30 per cent of the combined entity and a seat on the board.

Trading in Epitan shares began in Germany last week after the company listed on the Frankfurt stock exchange. The move follows on the heels of the company successfully completing a Level 1 ADR program in the US in July.

CEO Wayne Millen said the listing was an important step for the company to open up the European market. "We intend to further increase Epitan's profile with both institutional and private investors across Europe in the coming months. The US ADR listing in July proved very successful and we expect a listing in Germany will further broaden our international capital base," he said.

Frankfurt-based securities broker Seydler AG Securities has been engaged by Epitan to act as Market Maker for the company's shares on the electronic dealing system Xetra.